Hopeful Advances — Umbilical‑Cord Mesenchymal Stem Cells for Type 2 Diabetes
Introduction Umbilical‑cord mesenchymal stem/stromal cells (UC‑MSCs) are an exciting, rapidly advancing therapy showing real promise to improve glucose control, reduce insulin needs, and support metabolic recovery in people with type 2 diabetes (T2D). Early clinical trials and preclinical studies report meaningful improvements in HbA1c, insulin requirements, and glucose‑time‑in‑range, while safety in controlled studies has been encouraging. These results support further development and offer genuine hope for patients seeking better long‑term control. What the evidence shows Safety and optimism Practical takeaways for patients References